[go: up one dir, main page]

ES2194618T1 - Composicion oralmente desintegrable que comprende mirtazapina. - Google Patents

Composicion oralmente desintegrable que comprende mirtazapina.

Info

Publication number
ES2194618T1
ES2194618T1 ES00971346T ES00971346T ES2194618T1 ES 2194618 T1 ES2194618 T1 ES 2194618T1 ES 00971346 T ES00971346 T ES 00971346T ES 00971346 T ES00971346 T ES 00971346T ES 2194618 T1 ES2194618 T1 ES 2194618T1
Authority
ES
Spain
Prior art keywords
mirtazapine
oralally
disintegrable composition
disintegrable
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES00971346T
Other languages
English (en)
Other versions
ES2194618T3 (es
Inventor
Nijs Henrik De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194618(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of ES2194618T1 publication Critical patent/ES2194618T1/es
Application granted granted Critical
Publication of ES2194618T3 publication Critical patent/ES2194618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una unidad de dosificación para administración peroral, que comprende una formulación farmacéutica de mirtazapina como una sustancia activa y excipientes farmacéuticamente aceptables, caracterizada porque la unidad de dosificación es del tipo oralmente desintegrable, y la formulación comprende medios que impiden sustancialmente que la mirtazapina se libere oralmente.
ES00971346T 1999-10-13 2000-10-09 Nueva formulacion de mirtazapina. Expired - Lifetime ES2194618T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13
EP99203338 1999-10-13

Publications (2)

Publication Number Publication Date
ES2194618T1 true ES2194618T1 (es) 2003-12-01
ES2194618T3 ES2194618T3 (es) 2005-04-01

Family

ID=8240737

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00971346T Expired - Lifetime ES2194618T3 (es) 1999-10-13 2000-10-09 Nueva formulacion de mirtazapina.

Country Status (28)

Country Link
EP (1) EP1223914B1 (es)
JP (1) JP5561885B2 (es)
KR (1) KR100708560B1 (es)
CN (1) CN1173701C (es)
AR (1) AR026010A1 (es)
AT (1) ATE274899T1 (es)
AU (1) AU780379B2 (es)
BR (1) BR0014593A (es)
CA (1) CA2386547C (es)
CO (1) CO5251412A1 (es)
CZ (1) CZ20021315A3 (es)
DE (2) DE60013466T2 (es)
ES (1) ES2194618T3 (es)
HK (1) HK1046641B (es)
HU (1) HUP0203148A3 (es)
IL (2) IL148777A0 (es)
MX (1) MXPA02003519A (es)
NO (1) NO20021730L (es)
NZ (1) NZ518165A (es)
PE (1) PE20010699A1 (es)
PL (1) PL200858B1 (es)
PT (1) PT1223914E (es)
RU (1) RU2261098C2 (es)
SK (1) SK6452002A3 (es)
TR (1) TR200200978T2 (es)
TW (1) TWI256309B (es)
WO (1) WO2001026621A2 (es)
ZA (1) ZA200202293B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474190A1 (en) * 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
WO2005051349A2 (en) * 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
EP2001495A4 (en) * 2006-02-27 2010-12-08 Alexander Michalow METHODS OF REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATION
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
CA2852042C (en) * 2012-03-02 2018-05-01 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
US10603272B2 (en) 2015-02-27 2020-03-31 Kindred Biosciences, Inc. Stimulation of appetite and treatment of anorexia in dogs and cats
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农（肇庆）生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
DK0494972T3 (da) * 1989-10-02 1997-05-12 Cima Labs Inc Brusedosisform samt fremgangsmåde til administration heraf
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
AU678401B2 (en) * 1992-10-07 1997-05-29 Akzo Nobel N.V. Process for separating enantiomers from a racemic mixture
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
CO5251412A1 (es) 2003-02-28
NO20021730D0 (no) 2002-04-12
NO20021730L (no) 2002-05-30
ZA200202293B (en) 2003-06-20
CN1173701C (zh) 2004-11-03
KR20020038946A (ko) 2002-05-24
ES2194618T3 (es) 2005-04-01
WO2001026621A3 (en) 2001-10-11
PT1223914E (pt) 2004-11-30
BR0014593A (pt) 2002-06-11
IL148777A (en) 2013-10-31
EP1223914A2 (en) 2002-07-24
MXPA02003519A (es) 2002-08-20
JP2003511403A (ja) 2003-03-25
CZ20021315A3 (cs) 2002-07-17
AU780379B2 (en) 2005-03-17
KR100708560B1 (ko) 2007-04-19
AR026010A1 (es) 2002-12-26
HUP0203148A3 (en) 2004-06-28
ATE274899T1 (de) 2004-09-15
PE20010699A1 (es) 2001-07-06
EP1223914B1 (en) 2004-09-01
AU1023201A (en) 2001-04-23
DE60013466T2 (de) 2005-01-20
NZ518165A (en) 2004-03-26
HK1046641B (en) 2005-04-08
SK6452002A3 (en) 2002-09-10
PL200858B1 (pl) 2009-02-27
DE60013466D1 (de) 2004-10-07
HUP0203148A2 (hu) 2003-01-28
PL354584A1 (en) 2004-01-26
CA2386547A1 (en) 2001-04-19
IL148777A0 (en) 2002-09-12
RU2261098C2 (ru) 2005-09-27
DE1223914T1 (de) 2003-09-18
CN1378452A (zh) 2002-11-06
WO2001026621A2 (en) 2001-04-19
TWI256309B (en) 2006-06-11
CA2386547C (en) 2010-06-08
JP5561885B2 (ja) 2014-07-30
HK1046641A1 (en) 2003-01-24
RU2002112238A (ru) 2004-01-10
TR200200978T2 (tr) 2002-09-23

Similar Documents

Publication Publication Date Title
ECSP083351A (es) Composiciones farmacéuticas
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
NO20011471L (no) Nye orale vedvarende frigivelsesformuleringer
AP1954A (en) Controlled release compositions comprising nimesulide.
NO994409D0 (no) Stabilisering av syresensitive benzimidazoler med aminosyre/cyklodekstrin-kombinasjoner
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
AR034517A1 (es) Formulacion farmaceutica
ATE292453T1 (de) Antivirale arznei
AP2003002763A0 (en) Controlled release formulations for oral administration
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ECSP003685A (es) Formulaciones orales de liberacion controlada
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
CO5380015A1 (es) Una forma de unidad de dosis farmaceutica del tipo del tipo de capsulas rigidas que contiene clonixinato de lisina, un procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y/o antiinflamatorio
UY27345A1 (es) Formulación farmacéutica.
ECSP024290A (es) Composiciones farmacéuticas y uso de las mismas
MY145885A (en) Controlled release formulations for oral administration
ECSP003607A (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa